<DOC>
	<DOCNO>NCT01601093</DOCNO>
	<brief_summary>In propose study , investigator plan evaluate efficacy safety Ceftazidime Sodium Sulbactam Sodium Injection ( 2:1 ) treatment respiratory urinary tract acute bacterial infection .</brief_summary>
	<brief_title>Study Ceftazidime Sulbactam Sodium Injection ( 2:1 ) Treatment Respiratory Urinary Tract Infection</brief_title>
	<detailed_description>Ceftazidime third-generation cephalosporin . Ceftazidime sodium sulbactam sodium injection ( 2:1 ) play therapeutic role former inhibit bacterial cell wall synthesis，the latter make irreversible competitive inhibition β-lactamase.The antimicrobial effect ceftazidime enhance two combine . The compound specifically aim mechanism bacterial resistance , extend life ceftazidime treatment-resistant pathogen infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Cefoperazone</mesh_term>
	<mesh_term>Sulperazone</mesh_term>
	<criteria>1 . Patients qualify moderate severe acute respiratory urinary tract bacterial infection acute bacterial infection need systemic antibiotic therapy . 2 . Hospital patient good compliance clinic patient , 18 year old less 70 year old , Gender : . 3 . Patients take antibiotic medication screen period . 4 . Patients severe liver , kidney hematopoietic system disease ( Both AST ALT less 1.5 time upper limit normal Cr normal range ) 5 . Pathogenic bacteria resistant ceftazidime sensitive test drug contrast drug . 6 . Women childbearing negative pregnancy test agree take contraceptive measure trial . 7 . Patients volunteer sign informed consent . 1 . Patients hypersusceptibility test drug penicillin , βlactamase inhibitor 2 . Pathogenic bacteria sensitive ceftazidime resistant ceftazidime , test drug control drug . 3 . Patients need take antibiotic medicine concurrent infection . 4 . Patients take medicine affect efficacy evaluation safety evaluation aspirin , indomethacin , phenylbutazone , sulfanilamide , disulfiram probenecid trial . 5 . Patients take risk severe drug interaction drug combination . 6 . Patients complicate disease think affect efficacy evaluation poor compliance . 7 . Pregnant Lactating woman 8 . Drug addict alcoholic . 9 . Patients select trial . 10 . Patients participate clinical trial past three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Respiratory urinary tract infection</keyword>
	<keyword>Ceftazidime Sulbactam Sodium Injection ( 2:1 )</keyword>
	<keyword>Phase Ⅱ</keyword>
</DOC>